Empagliflozin

General Information

Empagliflozin Impurities and Empagliflozin

Daicel Pharma offers high-quality impurities for Empagliflozin, an active pharmaceutical ingredient. These impurities, including (2-chloro-5-iodophenyl)(2-fluoro-4-methylphenyl)methanone, (2-chloro-5-iodophenyl)(2-fluoro-5-methylphenyl)methanone, (2-chloro-5-iodophenyl)(2-fluorophenyl)methanone, (2,5-diiodophenyl)(2-fluorophenyl)methanone, and Empagliflozin Impurity 9, play a vital role in assessing the purity, reliability, and safety of Empagliflozin. Daicel Pharma also offers a customized synthesis of Empagliflozin impurities to cater to client requirements, with worldwide delivery options available.

Empagliflozin [CAS: 864070-44-0] is a medication that works by competitively inhibiting sodium-glucose co-transporter 2 (SGLT2; SLC5A2), which is primarily responsible for the reabsorption of glucose in the kidney It acts as a hypoglycemic agent and is a sodium-glucose transport protein subtype 2 inhibitors. It is also used in combination with other drug therapies. It is an adjunct to diet and exercise for treating type 2 diabetes mellitus.

Empagliflozin: Use and Commercial Availability  

Empagliflozin, marketed under Jardiance, is an antidiabetic agent for treating type 2 diabetes mellitus in adults. It is used alone or with other antidiabetic medications, including linagliptin and metformin. In 2016, the FDA approved an additional indication for Empagliflozin to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and cardiovascular disease. Empagliflozin has demonstrated efficacy in reducing hospitalizations for heart failure and cardiovascular mortality.

Empagliflozin Structure and Mechanism of Action

The chemical name of Empagliflozin is (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol. Its chemical formula is C₂₃H₂₇ClO₇, and its molecular weight is approximately 450.9 g/mol.

Empagliflozin inhibits Sodium-glucose co-transporter 2 (SGLT2) responsible for glucose reabsorption from the glomerular filtrate back into the circulation. It increases urinary glucose excretion.

Empagliflozin Impurities and Synthesis

Empagliflozin impurities are byproducts or substances present with the drug compound, Empagliflozin¹. The synthesis, analysis, and control of these impurities are crucial to ensure the safety and efficacy of the medication. The synthesis of Empagliflozin impurities involves identifying the potential pathways and reactions that can lead to their formation. Analytical methods are employed to detect and quantify these impurities in Empagliflozin, using techniques like high-performance liquid chromatography (HPLC) and mass spectrometry. Strict control measures are implemented during the manufacturing process to minimize impurities and maintain the quality of Empagliflozin.

Daicel Pharma offers a comprehensive Certificate of Analysis (CoA) for Empagliflozin impurity standards, including (2-chloro-5-iodophenyl)(2-fluoro-4-methylphenyl)methanone, (2-chloro-5-iodophenyl) (2-fluoro-5-methylphenyl)methanone, (2-chloro-5-iodophenyl)(2-fluorophenyl)methanone, (2,5-diiodophenyl)(2-fluorophenyl)methanone, and Empagliflozin Impurity 9. They generate from an analytical facility that complies with cGMP standards. The CoA provides a detailed characterization report with data obtained through techniques such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity analysis². We give additional data like 13C-DEPT upon request. Daicel Pharma synthesizes unknown Empagliflozin impurities or degradation products. Every delivery has a complete characterization report.